FOR IMMEDIATE RELEASE聽|聽March 22, 2015

Vitamin D may keep low-grade prostate cancer from becoming aggressive

Note to journalists: Please report that this research will be presented at a meeting of the American Chemical 中国365bet中文官网.

A press conference on this topic will be held Monday, March 23, at 1 p.m. Mountain time in the Colorado Convention Center. Reporters may check-in at Room 104 in person, or watch live on YouTube . To ask questions, sign in with a Google account.

DENVER, March 22, 2015 鈥� Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.

His team will describe the approach in one of nearly 11,000 presentations at the 249th National Meeting & Exposition of the American Chemical 中国365bet中文官网 (ACS), the world鈥檚 largest scientific society. The meeting is being held here through Thursday.

If a tumor is present in a prostate biopsy, a pathologist grades its aggressiveness on a scale known as the Gleason Grading System. Tumors with Gleason scores of 7 and above are considered aggressive and likely to spread, requiring surgical removal of the prostate gland (prostatectomy) or radiation therapy. In contrast, prostate tumors with Gleason scores of 6 and below are less aggressive, and in some cases may cause no symptoms or health problems for the duration of the man鈥檚 life.

In cases of low-grade prostate cancer, many urologists do not treat the disease, but instead do what鈥檚 called 鈥渁ctive surveillance,鈥� says Bruce Hollis, Ph.D., who is at the Medical University of South Carolina. 鈥淭he cure 鈥� meaning surgery or radiation 鈥� is probably worse than the disease, so they wait a year and then do another biopsy to see where the patient stands.鈥�

However, knowing that they have even low-grade prostate cancer can cause patients and their families excessive anxiety, which prompts some of the men to undergo an elective prostatectomy, despite the risk of complications such as infection, urinary incontinence and erectile dysfunction. But a man must wait 60 days from the time of his biopsy before he can undergo a prostatectomy, so that inflammation from the biopsy can subside.

Hollis wondered if giving these men vitamin D supplements during the 60-day waiting period would affect their prostate cancer. His previous research had shown that when men with low-grade prostate cancer took vitamin D supplements for a year, 55 percent of them showed decreased Gleason scores or even complete disappearance of their tumors compared to their biopsies a year before (J. Clin. Endocrinol. Metab., 2012, DOI: 10.1210/jc.2012-1451).

In a new randomized, controlled clinical trial, his team assigned 37 men undergoing elective prostatectomies either to a group that received 4,000 U of vitamin D per day, or to a placebo group that didn鈥檛 receive vitamin D. The men鈥檚 prostate glands were removed and examined 60 days later.

Preliminary results from this study indicate that many of the men who received vitamin D showed improvements in their prostate tumors, whereas the tumors in the placebo group either stayed the same or got worse. Also, vitamin D caused dramatic changes in the expression levels of many cell lipids and proteins, particularly those involved in inflammation. 鈥淐ancer is associated with inflammation, especially in the prostate gland,鈥� says Hollis. 鈥淰itamin D is really fighting this inflammation within the gland.鈥�

The protein most strongly induced by vitamin D was one called growth differentiation factor 15 (GDF15). Previous studies by other groups showed that GDF15 dials down inflammation, and many aggressive prostate cancers make little or no GDF15.

The new research suggests that vitamin D supplementation may improve low-grade prostate cancers by reducing inflammation, perhaps lessening the need for eventual surgery or radiation treatment. 鈥淲e don鈥檛 know yet whether vitamin D treats or prevents prostate cancer,鈥� says Hollis. 鈥淎t the minimum, what it may do is keep lower-grade prostate cancers from going ballistic.鈥�

Hollis notes that the dosage of vitamin D administered in the study 鈥� 4,000 U 鈥� is well below the 10,000鈥�20,000 U that the human body can make from daily sun exposure. 鈥淲e鈥檙e treating these guys with normal body levels of vitamin D,鈥� he says. 鈥淲e haven鈥檛 even moved into the pharmacological levels yet.鈥�

The researchers acknowledge funding from , the , and .

The American Chemical 中国365bet中文官网 is a nonprofit organization chartered by the U.S. Congress. With more than 158,000 members, ACS is the world鈥檚 largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive press releases from the American Chemical 中国365bet中文官网, contact [email protected].

###

Follow us:      

Media Contact

303-228-8406 (Denver Press Center, March 21-25)

Michael Bernstein
202-872-6042 (D.C. Office)
301-275-3221 (Cell)
m_bernstein@acs.org

Katie Cottingham, Ph.D.
301-775-8455听(颁别濒濒)
k_cottingham@acs.org

Vitamin D supplements may slow or reverse the progression of low-grade prostate cancers.
Credit:Kitty Ellis/iStock/Thinkstock